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ABSTRACT 
OBJECTIVE: To establish the role of the transcription factor Pax4 in pancreatic islet 
expansion and survival in response to physiological stress and its impact on glucose 
metabolism, we generated transgenic mice conditionally and selectively 
overexpressing Pax4 or a diabetes-linked mutant variant (Pax4R129W) in β-cells.  
RESEARCH DESIGN AND METHODS: Glucose homeostasis as well as β-cell 
death and proliferation were assessed in Pax4 or Pax4R129W overexpressing 
transgenic animals challenged with or without streptozotocin. Isolated transgenic 
islets were also exposed to cytokines and apoptosis was evaluated by DNA 
fragmentation or cytochrome C release. The expression profiles of proliferation and 
apoptotic genes as well as β-cell markers were studied by immunohistochemistry and 
quantitative RT-PCR. 
RESULTS: Pax4 but not Pax4R129W protected animals against streptozotocin-
induced hyperglycemia and isolated islets from cytokine-mediated β-cell apoptosis. 
Cytochrome C release was abrogated in Pax4 islets treated with cytokines. IL-1β 
transcript levels were suppressed in Pax4 islets whereas they were increased along 
with NOS2 in Pax4R129W islets. Bcl-2, Cdk4 and c-myc expression levels were 
increased in Pax4 islets while MafA, insulin and GLUT2 transcript levels were 
suppressed in both animal models. Long-term Pax4 expression promoted proliferation 
of a Pdx1-positive cell subpopulation while impeding insulin secretion. Suppression 
of Pax4 rescued this defect with a concomitant increase in pancreatic insulin content. 
CONCLUSIONS: Pax4 protects adult islets from stress-induced apoptosis by 
suppressing selective NF-κB target genes, while increasing Bcl-2 levels. Furthermore, 
it promotes dedifferentiation and proliferation of β-cells through MafA repression, 
with a concomitant increase in Cdk4 and c-myc expression.  
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INTRODUCTION 
 
Diabetes mellitus (DM) is a disease characterized by high levels of circulating blood 
glucose. The etiology involves insufficient release of insulin from pancreatic islet β-
cells and resistance of target tissues to the action of the hormone. The two most 
common forms of diabetes are Type 1 DM (T1DM) characterized by a destruction of 
β-cells (1) and Type 2 DM (T2DM) typified by β-cell failure combined with insulin 
resistance (2). Factors such as the environment and genetic predisposition are key 
determinants that influence development and progression of the disease. Genetic 
studies including linkage analysis, candidate gene approaches and more recently 
genome-wide association studies (GWAS) have identified at least 40 loci affecting 
risk of T1DM and 27 T2DM susceptibility genes (3-5). Although GWAS has been a 
powerful approach to yield new diabetogenes, susceptible gene loci for which 
functions may be altered by environmental factors such as pregnancy and obesity 
remain to be identified.    
 
One such susceptibility gene locus not highlighted by GWAS encodes the islet β-cell 
transcription factor Pax4. Expression of the pax4 gene is mandatory for the 
development and maturation of β-cells (6). Although detectable, Pax4 expression was 
found to be low in adult β-cells (7). Forced expression of Pax4 in embryonic α-cells 
induced a complete phenotypic change towards β-cells indicating that Pax4 is a 
master regulator of the β-cell genetic program (8).  
 
Mutations and polymorphisms in the pax4 gene have been associated with both 
T1DM and T2DM in several populations, contrasting with other diabetogenes for 
which association has only been linked to one or the other form of DM (7; 9). 
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Interestingly, we found that Pax4 expression is increased in Type 2 diabetic islet, an 
effect that is most likely mediated by high blood glucose levels (10). Together, these 
studies suggest that Pax4 may function as a survival and/or proliferation gene 
allowing mature islets to adapt in response to physiological cues. Consistent with this 
premise, Pax4 mRNA levels were increased in islets cultured in the presence of 
glucose, betacellulin, activin A and GLP-1 (10). Ectopic expression of mouse Pax4 in 
human or rat islets as well as in the mouse MIN6 cell line confered protection against 
cytokine-mediated cell death and promoted replication (11; 12). A diabetes-linked 
mutant variant R121W, identified in the Japanese population (13; 14), was less 
efficient in protecting human islets against cytokines (11).  
 
Although these in vitro studies suggest a fundamental role of Pax4 in β-cell survival 
and replication, the impact of Pax4 in vivo and its relation to diabetes remains to be 
established. Herein, we have generated two transgenic mouse lines that conditionally 
express Pax4 or its mutant variant R121W (PAX4R129W in mice) in β-cells. Our 
results demonstrate that conditional overexpression of Pax4 in adult β-cells protects 
transgenic animals against streptozotocin-induced hyperglycemia and isolated islets 
against cytokines, while animals expressing the mutant variant were susceptible to 
develop hyperglycemia and β-cell death by both treatments. Long-term expression of 
Pax4 in animals repressed MafA as well as insulin, resulting in blunted glucose-
induced insulin secretion suggesting dedifferentiation of β-cells.  
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RESEARCH DESIGN AND METHODS 
Transgenic animals. The pIRES2-DsRedexpress (Clontech) vector was used for the 
generation of the inducible Pax4 or the mutant variant Pax4 R129W cDNA cassette. 
The final construct contained the tetracycline responsive promoter, the rabbit β-globin 
intron followed by the Pax4 or Pax4R129W coding sequence. A myc-epitope and 
polyhistidine tag were added for detection purposes. DsRedexpress was included in 
the constructs in order to follow Pax4 induction using non-invasive in vivo imaging. 
Pax transgenic animals were crossed to RIPrtTA mice to generate double transgenic 
descendants with conditional expression of Pax4 or Pax4R129W specifically in β-
cells. Induction of transgene expression was achieved by providing 1 g/L of 
doxycycline (DOX) (Sigma-Aldrich) in the drinking water. The GLUT2 knockout 
mouse has been described elsewhere (15). The Geneva Veterinary Cantonal Office 
and the CABIMER animal committee approved all experiments. 
 
Glucose and insulin measurements. Animals were fasted overnight or for 4 hrs and 
injected intraperitoneally with 2g glucose/kg body weight (BW) or with 1 unit 
insulin/kg BW Actrapid (Novo Nordisk Pharma). Blood was collected from tail vein 
and glucose levels were measured with a Precision Xceed glucometer. Plasma insulin 
levels were measured at 0 and 15 minutes using a mouse insulin ELISA kit 
(Mercodia, SE). Pancreatic insulin content was determined using an insulin enzyme 
immunoassay kit (SPI-BIO/Bertin Pharma Biotech Division; Brunschwig, Basel, CH). 
 
Streptozotocin (STZ) Treatment. STZ was prepared in 0.1mM sodium citrate at pH 
4.5 and administered by intraperitoneal injection (200 mg STZ/kg BW). Blood 
glucose was determined before STZ injection, and then three times per week.  
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Mouse islet isolation. Pancreatic islets were isolated by collagenase (Roche, 
Switzerland) digestion, handpicked and maintained in 11.1 mM glucose/RPMI-1640 
(Invitrogen, Switzerland) supplemented with 10% fetal calf serum (FCS; Brunschwig 
AG, Switzerland), 100 Units/ml penicillin and 100 mg/ml streptomycin (Sigma, 
Switzerland).  
 
Quantitative real time PCR (Q-RT-PCR). Total RNA from islets was extracted using 
the RNeasy Micro Kit (Qiagen) and Q-RT-PCRs performed as described previously 
(16). Primer sequences were designed using the Primer Express Software (Applera 
Europe) and can be obtained upon request. 
  
Transfection studies. Transient transfections were performed as described previously 
(11). The luciferase reporter contructs, pFOX-Luc and pFOX-MafAR3-Luc (region 3 
of the MafA promoter specifying β-cell expression) were provided by Dr R. Stein 
(Vanderbilt University, USA).  
 
Cytokine treatment, apoptosis and Nitrite measurements. Islets were isolated from 
transgenic animals that had received 1 g/L DOX in the drinking water for 1 month. 
Islets were cultured for 48 hours in the presence of 1 ug/L DOX prior to the addition 
of 0.25 ng/ml IL-1β, 9.1 ng/ml TNFα and 100 ng/ml INFγ (R&D Systems). 
Apoptosis was evaluated 24 hours post-treatment using the Cell Death ELISA Plus kit 
(Roche). Alternatively, cell death was estimated by cytochrome C release. Dispersed 
islets were concentrated by cytospin onto glass slides and immunofluorescence was 
performed using anti-cytochrome C serum (BD Biosciences) and anti-serum for the 
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mitochondrial marker TOM 20 (Santa Cruz). Nitrite production in culture media was 
determined using the Griess reaction (Sigma).  
 
Proliferation assay. Mice were injected with 1 ml BrdU solution / 100 g BW (Roche) 
24h prior to sacrifice. Proliferation was detected by immunohistochemistry on 
pancreatic sections.  
 
Immunohistochemistry. For paraffin sections, pancreases were dissected and fixed in 
4% paraformaldehyde. Dehydration, embedding and sectioning were performed at 
either the Geneva or CABIMER Histology platform. Sections were rehydrated in 
ethanol and blocked in PBS containing 1% BSA and 0,1% Tween. The following 
primary polyclonal antibodies were used: guinea pig anti-insulin, mouse anti-
glucagon, rabbit anti-pdx1 (kindly provided by C. Wright, Vanderbilt University: 
1:200) rabbit anti-GLUT2 (1:200) and rabbit anti-MafA (Bethyl: 1:200). A mouse 
monoclonal BrdU was also used. The following secondary antibodies were added: 
Alexa Fluor 568 goat anti-guinea pig, Alexa Fluor 488 goat anti-mouse and Alexa 
Fluor 488 goat anti-rabbit. For cryostat sections, pancreases were frozen in liquid 
nitrogen, prior to sectioning and mounting. Sections were fixed in 4% 
paraformaldehyde and immunodetections were performed with the following primary 
polyclonal antibodies: rabbit anti-Pax4 (provided by Dr. Sosa-Pineda) and guinea pig 
anti-insulin. Secondary antibodies employed were: Alexa Fluor 568 goat anti-rabbit 
and Alexa Fluor 488 goat anti-guinea pig.  
 
Immunoblot analysis. Islets were harvested in lysis buffer (TRIS-HCl 0.05 M pH 7.5, 
EDTA 62.5 mM), cells disrupted by sonication and proteins resolved by 10% PAGE. 
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Gels were processed for immunoblotting using standard procedures. The following 
primary polyclonal antibodies were employed: rabbit anti-Pax4, goat DsRed (Santa 
Cruz), rabbit TFIIE-α (Santa Cruz). A goat anti-rabbit IgG antiserum conjugated to 
horseradish peroxidase (GE Healthcare) was then added and immunoreactive products 
were visualized by chemiluminescence (Pierce, Rockford, IL).  
 
Statistical analysis. Results are expressed as mean ± SEM. Statistical differences 
were estimated using the: unpaired t test, ANOVA with Bonferroni post hoc test or 
non-parametric Mann-Whitney test (*p<0.05, **p<0.01, ***p<0.001). 
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RESULTS 
Pax4 overexpression in adult pancreatic β-cells does not impact glucose 
homeostasis. In order to study in vivo the role of Pax4 and the impact of a mutant 
variant associated with diabetes in β-cell plasticity, we generated inducible double 
transgenic mouse lines, expressing RIP-rtTA along with either Pax4/DsRedexpress or 
Pax4R129W/DsRedexpress For simplicity, double transgenic rtTA/Pax4 and 
rtTA/Pax4R129W animals are denoted as Pax4 and Pax4R129W, respectively while 
control animals comprising single transgenic littermates are depicted as ST. Q-RT-
PCR revealed that both Pax4 and Pax4R129W transcripts were expressed to similar 
levels exclusively in islets of DOX-treated transgenic Pax4 animals, while expression 
of the transgenes was not detected in either control, single transgenic mice (ST) and 
double transgenics that had not been provided with DOX (Figure 1A). Western 
blotting confirmed expression of Pax4 as well as DsRedexpress in islets of the DOX-
treated animals (Figure 1B). Immunohistochemistry using either Pax4 or c-myc anti-
sera further substantiated specific expression of Pax4 in islets, and revealed co-
localization with insulin in most, but not all β-cells, suggesting β-cell-restricted 
expression of the transgene  (Figure 1C and D).  
 
In parallel, induction of DsRedexpress was monitored by non-invasive in vivo 
imaging in Pax4 transgenic animals. Fluorescence was detected in the abdominal 
region of anesthetized living animals treated with DOX for 48 hours (Figure S1A). 
Imaging of extracted organs confirmed expression of DsRedexpress specifically in the 
pancreas of treated animals, while other organs exhibited background fluorescence 
(Figure S1B).  
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Pax4 transgenic animals that received DOX for 1 month exhibited normal glucose 
tolerance and insulin sensitivity (Figure 1E and F). Consistent with this finding, 
glucose-induced insulin secretion was normal in islets isolated from Pax4 expressing 
mice as compared to control ST islets (245 ± 56 ng/ml versus 246 ± 55 ng/ml). 
Similar results were obtained with Pax4R129W animals (data not shown). These 
results demonstrate that conditional expression of Pax4 can be specifically achieved 
in islet β-cells and that its forced expression does not alter glucose homeostasis in 
double transgenic animals. 
 
Overexpression of Pax4 but not Pax4R129W protects mice against STZ-induced 
hyperglycemia. To assess the protective role of Pax4 in vivo, DOX-treated Pax4 or ST 
animals were challenged with a single high dose of STZ to destroy β-cells. ST 
animals rapidly developed hyperglycemia while Pax4 overexpressing animals 
remained normoglycemic throughout the experiment (Figure 2A). To confirm that 
Pax4 was mediating the protection against STZ-induced hyperglycemia, DOX was 
removed on day 27 and animals in group A received 14 days later a second STZ 
injection. Group A animals developed hyperglycemia similar to that observed in ST 
animals while Pax4 animals that did not receive a second STZ injection (group B) 
remained normoglycemic (Figure 2A). In an independent set of experiments, animals 
continuously exposed to DOX and re-challenged with a second high dose of STZ did 
not develop hyperglycemia confirming Pax4-dependent protection even after two high 
doses of STZ (Figure 2B). Pax4R129W animals challenged with a single dose of STZ 
developed an intermediate level of hyperglycemia indicating that the diabetes-
associated mutant is less efficient in protecting mice against stressed-induced 
hyperglycemia (Figure 2C). Immunohistochemistry combined with morphometry 
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analysis revealed a clear reduction in insulin+ cells with a concomitant increase in 
glucagon+ cells in STZ treated ST animals as compared to what was observed in 
untreated mice (Figure 2D, Figure S2A and S2B). In contrast, islet morphology and 
cell composition in Pax4-overexpressing animals challenged with either 1 or 2 doses 
of STZ were similar to those of islets from control animals (Figure 2D, Figure S2A 
and S2B). Islets from Pax4R129W mice exhibited less insulin staining suggesting a 
partial loss of β-cells correlating with intermediate hyperglycemia (Figure 2D). These 
results show that overexpression of Pax4 protects β-cells against multiple STZ 
challenges and prevents development of hyperglycemia while the mutant is less 
effective. 
 
Pax4 but not Pax4R129W protects islets against cytokine-induced apoptosis.   To 
further assess the protective action of Pax4, islets isolated from either Pax4 or 
Pax4R129W transgenic animals were treated with cytokines. Pax4 islets were 
protected against cytokine-induced cell death, as compared to ST control animals that 
displayed a 3-fold increase in cell death in the presence of cytokines (Figure 3A). 
Islets isolated from Pax4R129W animals exhibited a similar degree of apoptosis as 
compared to cytokine-treated ST animals (Figure 3A).  
  
Exogenous Il-1β was shown to induce endogenous levels of IL-1β and to lead to 
human islet β-cell death (17). Interestingly, IL-1β transcript levels were suppressed 
by 50% in islets isolated from Pax4 overexpressing animals. In contrast, Pax4R129W 
mutant mice exhibited a 2-fold increase in IL-1β transcript levels as compared to 
control untreated ST islets (Figure 3B). A parallel modulation in transcript levels of 
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the IL-1β antagonist was observed in both transgenic animal models whereas 
expression levels of the IL-1β receptor remained unaltered (Figure 3B).  
 
Mitochondrial cytochrome C release is blunted in Pax4-overexpressing islets 
treated with cytokines. A hallmark of cytokine-mediated cell death is the activation of 
the NF-κB pathway which leads to enhanced NOS2 and COX2 expression and the 
downstream increase in nitric oxide (NO) production, ultimately resulting in 
cytochrome C release from mitochondria (18). Consistent with this model, islets 
isolated from Pax4 mice and exposed to cytokines in the absence of DOX exhibited a 
2.5-fold increase in cytochrome C release. In contrast, cytochrome C release was 
abrogated in DOX-treated Pax4 islets whereas Pax4R129W overexpressing islets 
displayed a 3-fold increase as compared to non-cytokine treated islets (Figure 4A and 
B). Interestingly, NOS2 transcript levels were only significantly elevated in 
Pax4R129W islets while COX2 levels were augmented in both mutant and wild type 
Pax4 islets (Figure 4C). Despite differences in NOS2 expression, both Pax4 and 
Pax4R129W islets presented a significant increase in cytokine-induced nitrite 
production, an indicator of NO production (Figure 4D). However, Pax4 islets 
displayed a trend towards a small decrease in nitrite production as compared to non-
DOX treated islets. 
 
Overexpression of Pax4 alters expression of MafA, GLUT2, insulin and Bcl2. To 
further delineate the mechanism by which Pax4 protects β-cells from either STZ- or 
cytokine-induced apoptosis, mRNA expression levels of key β-cell markers as well as 
those of anti-apoptotic genes were determined in islets of Pax4 and Pax4R129W 
overexpressing animals (Figure 5A). Transcript levels of Pdx1 and Pax6 were not 
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altered in Pax4 or Pax4R129W overexpressing islets whereas MafA, GLUT2 and 
insulin levels were decreased in both animal models. Immunohistochemistry 
confirmed decreased MafA and GLUT2 protein levels in islets of Pax4 expressing 
mice (Figure 5B and C). Bcl-2 but not Bcl-xL expression levels were increased 3-fold 
specifically in Pax4 islets as compared to control animals without DOX (Figure 5A). 
 
As insulin and GLUT2 are target genes of MafA (19; 20) and since a Pax4 consensus 
sequence was predicted in the region 3 of the MafA promoter (21), we investigated 
whether Pax4 could directly regulate MafA transcription. Pax4 as well as 
Pax4R129W dose-dependently inhibited a luciferase reporter construct driven by 
region 3 of the MafA promoter, reaching 50% inhibition at the highest dose (Figure 
5D). Repression was specific as Pax4 was unable to inhibit the control pFOX-Luc 
construct. However, Pax4 failed to interact with the putative binding site identified in 
this MafA region (MafAR3Pax4), while it displayed specific binding to the G3 
element of the glucagon promoter (Figure S3A) (22). Surprisingly, Pax6 exhibited 
strong interaction with MafAR3Pax4, thus identifying a new binding site for this 
factor within the MafA R3 promoter region (23). Reporter assays revealed a Pax6 
dose-dependent activation of this promoter region, which was blunted by increasing 
amounts of Pax4 (Figure S3B).  
 
GLUT2 heterozygous mice are protected against STZ-induced hyperglycemia. 
Streptozotocin is selectively taken up by β-cells through GLUT2 (24). As GLUT2 
levels were decreased in Pax4 overexpressing islets, we determined whether such 
inhibition would be sufficient to protect β-cells against STZ. To this end, the GLUT2 
heterozygous mouse model was employed in order to directly measure the impact of 
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the glucose transporter in STZ-mediated cell death. Transcript levels of the 
transporter were reduced by 60% in heterozygous GLUT2 mice (Figure 6A). Similar 
to Pax4 mice, these animals were refractory to STZ-induced β-cell apoptosis while 
control wild type littermates were sensitive to the toxic agent (Figure6B). These 
results suggest that the protective effect of Pax4 against STZ is potentially partially 
conveyed by reduced GLUT2 expression. However despite similar lower levels of 
GLUT2, Pax4R129W mice are only partially protected against STZ suggesting that 
alternative detrimental processes are associated with the mutant phenotype.  
 
Transient overexpression of Pax4 improves total pancreatic insulin content after 4 
months. Adenoviral-mediated overexpression of Pax4 in cultured rat islets was shown 
to hamper insulin secretion (11). Although this effect was not observed in Pax4 
transgenic animals treated with DOX for one month, plasma insulin levels in response 
to glucose were greatly reduced in animals treated for 4 months (Figure 7A). This was 
accompanied by glucose intolerance in these animals (Figure 7B). Furthermore, 
morphological analysis of pancreas isolated from Pax4 expressing mice revealed 
altered islet architecture typified by enlarged intercellular spaces, corresponding to 
widely opened capillaries, which were seldom observed after sacrifice of control mice 
(Figure S4). To determine whether this effect was reversible, DOX was removed from 
the drinking water of 4-month treated animals to repress Pax4 expression and plasma 
insulin levels were re-evaluated 1-month after. Consistent with our premise, the rise 
in plasma insulin levels in response to glucose was rescued in transgenic animals 
subsequent to removal of DOX  (Figure 7C). Total pancreatic insulin content was 
significantly increased in Pax4 mice after removal of DOX (Figure 7D). 
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Long-term (4-months) but not short-term (1-month) Pax4 overexpression increases 
islet β-cell replication. The increase in insulin content observed after DOX removal 
(Figure 7D) suggests that long-term expression of Pax4 may induce β-cell replication. 
Consistent with this premise, islets isolated from 4-month but not 1-month DOX-
treated Pax4 mice that showed reduced glucose-induced plasma insulin levels (Figure 
7A), exhibited increased BrdU labeling of β-cells as compared to control ST islets 
(Figure 8A). This was accompanied by an overall non-significant increase in the 
proportion of β-cells (Figure 8B). A BrdU+/insulin- cell subpopulation was also 
detected specifically in Pax4 overexpressing islets (Figure 8A). These cells were also 
negative for glucagon and somatostatin staining. As Pax4 overexpression impedes 
insulin transcription (Figure 5A), we reasoned that these cells were likely β-cells with 
low levels of insulin. Therefore, Pdx1 was used as an alternative β-cell marker. Most 
BrdU+ cells were also Pdx1+ and the total percentage of these cells was equivalent to 
the sum of the insulin+ and insulin- cell subpopulations that were BrdU+ (compare 
Figure 8A and 8C). Despite a significant increase in overall proliferation (Figure 8C), 
we did not detect an increase in the total population of Pdx1+ cells (Figure 8D) or an 
increase in islet mass due to low number of proliferating cells. Consistent with 
increased long-term cell replication, c-myc as well as Cdk4 but not Cdk2 or 6 were 
increased in Pax4 overexpressing islets (Figure 8E). 
 
DISCUSSION 
Our study highlights the physiological role of Pax4 in vivo as a regulator of mature 
islet β-cell survival and proliferation. Pax4 prevented development of hyperglycemia 
in animals exposed to environmental insults such as repeated STZ challenges, and 
protected islets against cytokine-mediated apoptosis. The diabetes-associated R129W 
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mutation was less efficient in protecting animals against STZ-induced hyperglycemia. 
The detrimental effect of the mutation was only revealed in the presence of harmful 
environmental cues highlighting the interplay between genetic determinants and the 
environment in the development of hyperglycemia (25). Thus, in response to 
physiological demand or pathophysiological situations, Pax4 expression may be 
transiently induced to protect and to compensate β-cell mass whereas the mutant 
variant would be unable to achieve this, resulting in the gradual loss of β-cells and 
ultimately diabetes. The regulation of Pax4 expression by environmental factors 
provides a likely explanation for the failure of GWAS to identify Pax4 as a diabetic 
susceptibility gene as well as for discrepancies in different studies to validate the 
association of Pax4 polymorphisms with T2DM in various ethnic populations (7). 
 
One mechanism by which Pax4, but not Pax4R129W, protects β-cells against STZ- 
and cytokine-induced cell death may, in part, be connected to the regulation of 
selective target genes of the NF-κB signaling cascade (26). Indeed, we found that 
transcript levels of IL-1β, the predominant cytokine implicated in the activation of the 
NF-κB pathway, was decreased in Pax4 expressing islets whereas it was increased in 
Pax4R129W islets. Consistent with NF-κB activation, transcript levels of its target 
gene nos2 were selectively higher in mutant animals whereas levels of the target gene 
cox2 were increased in both Pax4 and Pax4R129W. NOS2 is involved in NO 
production and downstream stimulation of apoptosis (26) while the COX2-generated 
metabolite prostaglandine E2 was found to be anti-apoptotic (27). As IL-1β was 
shown to auto stimulate expression levels of endogenous IL-1β (17) and to induce β-
cell death in human islets (28), Pax4-mediated inhibition of IL-1β transcription with a 
concomitant increase in COX2 levels may confer increased resistance to apoptosis. In 
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contrast, elevated basal levels of IL-1β and NOS2 in Pax4R129W overexpressing 
mice may sensitize islet cells to NO-induced apoptosis. Furthermore, since NO can 
also be released from islets exposed to STZ, (29), we suggest that Pax4R129W mice 
are more prone to cell death than GLUT2 heterozygous mice due to an increase 
predisposition to NO-mediated apoptosis. Interestingly, the levels of the IL-1β 
antagonist, IL-1Ra, were also increased in mutant islets suggesting restoration of an 
IL-1β to IL-1Ra ratio which prevents activation of the apoptotic program (30). 
Consistent with this model several putative Pax4 binding sites were predicted in both 
the il-1β and nos2 gene promoters.  
 
Despite differences in Il-1β levels, both Pax4 and Pax4R129W expressing islets 
exhibited similar levels of NO production upon exposure to cytokines. This indicates 
that the NF-κB signaling pathway can still be fully activated upon strong exogenous 
stimulation and that the protection conveyed by Pax4 is relayed through additional 
gene product that block the NF-κB apoptotic pathway. One such candidate gene could 
be Bcl-2, which regulates the mitochondrial response to pro-apoptotic signals, 
preventing the release of cytochrome C and the subsequent activation of the cell death 
program (31). Indeed, we found that Pax4- but not Pax4R129W-overexpressing islets 
exhibited increased expression of Bcl-2 with blunted cytokine-mediated cytochrome 
C translocation. Corroborating our results, Bcl-2 overexpression was shown to protect 
mouse and human islets against cytokine-induced apoptosis (32; 33). In contrast to 
our previous study in rat islets overexpressing Pax4 (11), we did not detect increased 
expression of Bcl-xL in mouse islets possibly due to species differences.  
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Overexpression of either Pax4 or Pax4R129W markedly perturbed expression of 
MafA and two of its target genes glut2 and insulin, which are key markers of mature 
β-cells. Although both Pax4 proteins suppressed the activity of a luciferase construct 
harboring the MafA gene promoter region 3, we could not detect Pax4 binding to a 
putative binding site within this region. Preliminary ChIP assay results revealed no 
convincing interaction of Pax4 with region 3 suggesting an indirect effect of Pax4 on 
MafA expression. However, we have previously demonstrated that Pax4 impairs 
glucagon and insulin gene transcriptions through direct protein interaction with Pax6 
(22). Our current data demonstrating that Pax4 blunts Pax6-stimulated MafA 
promoter activity suggest a similar mechanism as the one delineated for glucagon and 
insulin. Inhibition through protein-protein interaction, and not direct DNA binding 
activity, would explain the inhibitory effect observed with the weaker DNA-
interacting mutant variant. 
 
Long-term overexpression of Pax4 resulted in a blunted glucose-induced rise in 
plasma insulin levels, an effect reversible upon inhibition of Pax4. A recent study also 
reported impaired glucose-induced insulin secretion in an animal model in which 
Pax4 was constitutively overexpressed in α-cells. These cells were converted to β-
cells that remained functional for up to 4 weeks before an unexpected decline in 
insulin secretion occurred. Animals ultimately died of hyperglycemia (8). We would 
therefore like to propose the Pax4-dependent impaired insulin secretion is mediated 
by the long-term repression of the mature β-cell marker MafA and insulin.  
 
Aberrant expression of Pax genes were shown to convert cells to a less differentiated 
state and to promote self-renewal as well as increasing survival (34). Consistent with 
 19 
this premise, a subpopulation of replicating Pdx1+/insulin- cells was identified in Pax4 
overexpressing islets. These cells were also negative for both glucagon and 
somatostatin suggesting, that they likely represent insulin-deprived β-cells resulting 
from repression of MafA and insulin transcription by Pax4. A similar β-cell 
subpopulation was recently characterized in vitro (35). These cells displayed impaired 
glucose-induced insulin secretion and were prone to proliferation in response to 
activin A (36). More importantly, MafA and GLUT2 transcript levels were lower in 
this subpopulation whereas Pax4 levels were higher. Taken together, these results 
suggest that Pax4 under physiological conditions is most likely expressed in a 
subpopulation of β-like cells prone to proliferation. Substantiating this hypothesis, 
Cdk4 and c-myc transcript levels were increased in Pax4 overexpressing islets. 
Adenoviral-mediated Cdk4 expression was shown to increase mouse islet cell 
proliferation (37) while its repression causes insulin-deficiency and hyperglycemia 
(38). Similarly, β-cell specific overexpression of c-myc caused downregulation of 
insulin gene expression with a concomitant increase in proliferation as well as 
apoptosis (39). The concept that a fraction of islet β-cells respond to proliferation 
would provide a mechanism by which a pool of mature cells can rapidly undergo 
regulated replication to compensate for loss cells while quiescent cells retain the 
ability to regulate blood glucose. 
 
In summary, our study establishes an important role for Pax4 in mature islet 
physiology by increasing β-cell survival and proliferation. The detrimental impact of 
Pax4 mutations is only revealed upon environmental stresses, which reinforces the 
critical role of gene-environment interaction in the development of diabetes.  
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FIGURE LEGENDS 
 
Figure 1. Selective conditional overexpression of either Pax4 or Pax4R129W in 
mouse β-cells. (A) Double transgenic animals bearing either the pTRE-Pax4 or 
Pax4R129W-myc-His-IRES-DsRedexpress construct along with the RIP-rtTA 
transgene (denoted as Pax4 or Pax4R129W) were provided with 1g/L DOX (DOX) in 
drinking water for one month. Pax4 and Pax4R129W transcript levels were then 
evaluated by Q-RT-PCR. Relative mRNA levels were normalized to the transcript 
levels of the housekeeping gene cyclophilin and/or rps29. Data were calculated as 
fold change compared to single transgenic animals (ST). (B) DOX-induced Pax4 and 
DsRedexpress proteins were confirmed by Western blot analysis. 
Immunofluorescence analysis using anti-myc (C) or anti-Pax4 (D) sera revealed 
specific expression of the Pax4 protein only in the pancreatic islet β-cells of animals 
that received DOX. Of note, the intense green staining within the islet in the c-myc (-) 
DOX image is non-specific. (E) Glucose tolerance tests were performed on control ST 
animals and Pax4 animals treated or not with DOX. (F) Insulin tolerance tests were 
also performed on the same animals. Data are expressed as mean ± SEM from 3 to 6 
animals per group.  
 
Figure 2. Pax4 overexpressing animals are protected against streptozotocin-
induced hyperglycemia. (A) A single high dose of streptozotocin (STZ; 200 mg / Kg 
BW) was injected in control (ST) as well as in Pax4 animals treated with DOX (group 
A and B). Blood glucose levels were measured 3 times per week, for up to 58 days. 
All animals prior to STZ injection received DOX in the drinking water for 1 month 
starting at weaning. To further assess the protective role of Pax4, DOX was removed 
from the drinking water at day 27. Blood sugar levels were followed for 2 weeks 
before a second injection of STZ on day 41 was administered to group A (arrow) 
while group B received only the vehicle. (B) Alternatively, Pax4 animals maintained 
on DOX (group D) were challenged with a second high dose of STZ (arrow) and 
glycemia was monitored for an extra 22 days. Group C animals were sustained on 
DOX without a STZ rechallenge. (C) Pax4, Pax4R129W and ST animals were 
injected with STZ and glycemia monitored for 30 days. Data are expressed as the 
mean ± SEM from 3 to 9 animals per group. Statistical difference was tested by the 
non-parametric Mann-Whitney test (significance from p<0.05). (D) 
Immunohistochemical analysis of glucagon (green) and insulin (red) on representative 
pancreatic paraffin sections from DOX treated ST, Pax4 and Pax4R129W mice 
challenged or not with STZ. Animals were sacrificed on day 27 and paraffin sections 
were prepared from ST animals that received citrate buffer injection (a, d, g, j) or 
challenged with STZ (b, e, h, k) as well as Pax4 (c, f, i, l) or Pax4R129W (c', f', i', l') 
animals injected with STZ injection. Bars, 50 µm for a, d, g, j and 25 µm for 
remaining panels.  
 
 
Figure 3. Isolated islets from Pax4 transgenic mice are protected against 
cytokine-induced apoptosis. (A) Freshly isolated islets from single transgenic 
animals (ST), double transgenic animals Pax4 (left panel) and Pax4R129W (right 
panel) were cultured with 1 µg/L DOX for 48h, and subsequently challenged with a 
mix of IL-1β, IFN-γ and TNF-α. Cell death was measured using a cell death detection 
ELISA kit. Results are expressed as mean ± SEM of 4 and 3 independent experiments 
relative to non-treated islets. (B) IL-1β, IL-1Ra and IL-1R1 mRNA expression levels 
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were measured by Q-RT-PCR in either Pax4 or PaxR129W overexpressing animals. 
Relative mRNA levels were normalized to the transcript levels of the housekeeping 
gene cyclophilin. Data were calculated as fold change compared to single transgenic 
animals (ST) that received DOX (represented by dash line) and expressed as the mean 
± SEM from 3 to 5 animals per group. Statistical difference was tested by one-way 
ANOVA with Bonferroni post-hoc test (*p<0.05, **p<0.01, ***p<0.001). 
 
Figure 4. Pax4 overexpression protects from cytokine-induced β-cell death by 
impeding mitochondrial cytochrome C release. (A) Immunofluorescent 
localization of cytochrome C (green) TOM-20 (red) and DAPI (blue) within islet cells 
treated with or without cytokines in the presence or absence of either Pax4 or 
Pax4R129W expression. (B) Quantification of cytochrome C release from the 
mitochondria. Metamorph ® software was used to measure the area of red 
fluorescence (TOM-20) and green fluorescence (cytochrome C). A total of 20 images 
each containing 4-5 cells, were taken per condition and per mouse, in three 
independent experiments. Total green fluorescence (cytochrome C) area was then 
divided by total red fluorescence (TOM-20) area. Values greater than 1 means that 
cytochrome C is external to the mitochondria, and values equal or lower than 1 means 
that it is inside the organelle. (C) Q-RT-PCR analysis of nos2 and cox2 transcript 
levels in islets of Pax4 and Pax4R129W transgenic animals treated with DOX. 
Relative mRNA levels were normalized to the transcript levels of the housekeeping 
gene cyclophilin. Data were calculated as fold change compared to single transgenic 
animals (ST) that received DOX (represented by dash line) and expressed as the mean 
± SEM from 4 animals per group.  (D) Nitrite release in culture media was estimated 
using the Griess reagent. Data were expressed as the means ± SEM from 3 
independent experiments. Statistical difference was tested by one-way ANOVA with 
Bonferroni post-hoc test (*p<0.05, **p<0.01, ***p<0.001). 
 
Figure 5. Induction of Pax4 in islets suppresses MafA, insulin and GLUT2 
expression whereas it increases Bcl-2. (A) Q-RT-PCR was performed on islets 
isolated from DOX-treated Pax4 and Pax4R129W animals. Relative mRNA levels 
were normalized to the transcript levels of the housekeeping gene cyclophilin and/or 
rps29. Data were calculated as fold change compared to single transgenic animals 
(ST) that received DOX (represented by a dashed line) and expressed as the mean ± 
SEM from 4 - 5 animals per group. Statistical difference was tested by one-way 
ANOVA with Bonferroni post-hoc test (*p<0.05, **p<0.01, ***p<0.001). 
Immunohystochemistry analysis of MAFA (B) and GLUT2 (C) was performed on 
pancreatic sections from Pax4 overexpressing animals and in control ST animals 
treated with DOX. (D) Transient co-transfection studies using INS-1E cells were 
performed with increasing amounts of either Pax4 or PaxR129W expression vectors 
(0.25, 0.50, 0.75 and 1 mg) along with 500 ng of either pFOX-Luc or pFOX-
MafAR3-Luc. Data are presented as fold change of basal luciferase activity and 
expressed as the mean ± SEM of three experiments (*p<0.05).  
  
Figure 6. GLUT2 heterozygous mice are protected against STZ-mediated 
hyperglycemia. (A) GLUT2 mRNA expression levels were measured by Q-RT-PCR 
in isolated islets from GLUT2+/+ and GLUT2+/- mice. Relative mRNA levels were 
normalized to the transcript levels of the housekeeping gene cyclophilin. Data were 
calculated as fold change compared to GLUT2+/+ mice, and expressed as the means ± 
SEM from 3 animals per group. Statistical difference was tested by unpaired t test 
 27 
(***p<0.001). (B) GLUT2+/+ and GLUT2+/- male mice were injected with a single 
dose of STZ (200 mg / Kg BW) and glycemia monitored for up to 7 days. Data are 
expressed as the mean ± SEM from 3 animals per group. Statistical difference was 
tested by the non-parametric Mann-Whitney test.  
 
Figure 7. Transient overexpression of Pax4 improves glucose tolerance and total 
pancreatic insulin content after 4 months. (A) Plasma insulin levels were measured 
15 min after an injection of 2 g/kg body weight (BW) glucose in Pax4 overexpressing 
animals as well as in ST animals that were maintained on DOX for 4 month. (B) 
Glucose tolerance   tests were performed on the same animals. (C) DOX treatment 
abolished for 1 month and plasma insulin levels were re-evaluated as in (A). (D) Total 
pancreatic insulin content was measured as indicated in the experimental procedures 
in Pax4 animals that received DOX for 4 months and then not treated for one month. 
Data are expressed as mean ± SEM from 5 animals per group. Statistical difference 
was tested by t test (*p<0.05). 
 
Figure 8. Long-term expression of Pax4 increases β-cell proliferation. (A) 
Pancreatic sections from 3 months Pax4 overexpressing animals were co-
immunostained for BrdU and Insulin. Approximately 8000 β-cells were counted in 
blind, from 5 different pancreatic sections, separated 50µm from each other. INS+, 
insulin-postive β-cells; INS-, insulin-negative β-cells; ND, not detected (B) The 
proportion of INS+ and INS- cells was counted on the slides from section (A). (C) 
Pancreatic sections from 3 months Pax4 overexpressing animals were co-
immunostained for BrdU and Pdx-1. Cell counting was performed as in section (A). 
(D) Total number of Pdx-1+ cells was counted on the slides from section (B). (E) 
Transcript levels of proliferative genes were assessed by QRT-PCR on freshly 
isolated islets from Pax4 overexpressing animals. Relative mRNA levels were 
normalized to the transcript levels of the housekeeping gene cyclophilin. Data were 
calculated as fold change compared to single transgenic animals (ST) that received 
DOX (denoted as dash line) and expressed as the mean of ± SEM from 5 animals per 
group. Statistical difference was tested by t test (*p<0.05). 
 
 
 
 
 
 
 
 
 
Figure 1. Hu He et al.
A B
ST Pax4
Pax4
DSRED
TFIIE-α
Dox
C-MYC MERGE
E F
C
DAPI
(-
) D
O
X
Fo
ld
 in
cr
ea
se
 a
s 
co
m
pa
re
d
to
 S
T 
co
nt
ro
l a
ni
m
al
s
DOX - - - -+ +
Pax4 Pax4R129W
30
25
20
15
10
5
0
n=6
- - +
(+
) D
O
X
MERGEDAPI INSULIN
(-
) D
O
X
(+
) D
O
X
D
25 µm
ST ST
25 µm
INSULIN Pax4
Figure 2. Hu He et al.
D
ST       Pax4
a b c
e f
g h i
j k l
d
D
AP
I
G
LU
C
AG
O
N
IN
SU
LI
N
M
ER
G
E
Pax4R129W
c’
f’
i’
l’
25 µm50 µm
STZ - + + +
(days)
A
Bl
oo
d 
gl
uc
os
e 
(m
M
)
B
Bl
oo
d 
gl
uc
os
e 
(m
M
)
- dox+ dox
n = 5-9
0
5
10
15
20
25
30
0 2 4 6 8 131517202224272931343638414345474951535558
ST + STZ
Pax4 + STZ, group A
Pax4 + STZ, group B
n = 3-9
0
5
10
15
20
25
30
0 2 4 6 8 13 15 17 20 22 24 27 30
ST + STZ
Pax4R129W + STZ
Pax4 + STZ
(days)
C
0
5
10
15
20
25
30
35
0 5 10 15 20 25 30 35 40
Pax4 + STZ, group C
Pax4 + 2nd dose STZ, group D
ST + STZ
n = 3-6
(days)
Bl
oo
d 
gl
uc
os
e 
(m
M
)
Figure 3. Hu He et al.
A
B
0
0.2
0.4
0.6
0.8
1.0
1.2
 
C
el
l d
ea
th
 (A
45
0)
Dox                      +          +               +          +
INFγ/IL1β/TNFα   -          +                -          +
ST               Pax4
n = 4
*
***
 
C
el
l d
ea
th
 (A
45
0)
0
0.2
0.4
0.6
0.8
1.0
1.2
n = 3
ST                        Pax4R129W
n.s
Dox                      +          +               +          +
INFγ/IL1β/TNFα   -          +                -          +
***
***
n.s.
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
m
R
N
A
 fo
ld
 in
cr
ea
se
 a
s
co
m
pa
re
d 
to
 c
on
tro
l
n = 3-5
***
***
* *
PAX4
Pax4R129W
IL-1β IL-1Ra IL-1R1
Pax4
Pax4R129W
DOX
INFγ+IL1β+TNFα
Figure 4. Hu He et al.
A
B
C
-
- -
-+
+ +
+
30 µm
0
1
2
3
4
5
6
NOS2 COX2
Pax4
Pax4R129W
m
R
N
A
 fo
ld
 in
cr
ea
se
 a
s
co
m
pa
re
d 
to
 c
on
tro
ls
n=4
D
***
***
***
**n = 3
ns
DOX
INFγ/IL1β/TNFα
ns
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
R
el
at
iv
e 
A
re
a 
C
yt
oc
hr
om
e 
C
 
/ T
O
M
20
-
- -
-+ +
++
Pax4
Pax4R129W
N
itr
ite
 (µ
M
)
DOX
n = 3
          -         -         +        +
          -        +         -         +
*
*
*
*
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
INFγ/IL1β/TNFα
Figure 5. Hu He et al.
A
B
GLUT2 MERGEDAPI INSULIN
S
T
P
ax
4
25 µm
MAFA MERGEDAPI INSULIN
S
T
P
ax
4
C
25 µm
%
 c
ha
ng
e 
as
 c
om
pa
re
d
to
 c
on
tro
l
Pax4 Pax4
C
0
20
40
60
80
100
120
140
Pax4R129W
C C
pFOX-Luc pFOX-MafAR3Luc
** **
n=4 n=6-9
D
A
m
R
N
A 
fo
ld
 in
cr
ea
se
 a
s
co
m
pa
re
d 
to
 c
on
tro
ls
B
***
n = 3
1.2
1.0
0.8
0.6
0.4
0.2
0
Glut2+/+ Glut2+/-
Figure 6. Hu He et al.
n = 3
0
5
10
15
20
25
30
35
0 2 4 7 (days)
B
lo
od
 G
lu
co
se
 (m
M
)
Glut2+/+ + vehicule
Glut2+/+ + STZ 
Glut2+/- + STZ 
Figure 7. Hu He et al.
Bl
oo
d 
gl
uc
os
e 
(m
M
)
ST
Pax4
0
5
10
15
20
25
30
35
0 20 40 60 120
time (min)
n=5
GTT:
4 MONTHS DOX
B
*
*
*
A
C D
PLASMA INSULIN LEVELS:
4 MONTHS DOX
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40 n = 5
 ST  Pax4
Dox                  +       +              +        +
Glucose           -        +              -         +
Time (min)       0      15             0       15
PLASMA INSULIN LEVELS:
AFTER DOX REMOVAL
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40 n = 5
TOTAL INSULIN CONTENT
0
10
20
30
40
50
60
70
 
In
su
lin
 (µ
g/
L)
In
su
lin
 (µ
g/
L)
 ST  Pax4
Dox                  +       +              +        +
Glucose           -        +              -         +
Time (min)       0      15             0       15
µ
g 
in
su
lin
/p
an
cr
ea
s
n = 5
 ST Pax4
Figure 8. Hu He et al.
n = 5
A
D
B
Cdk2 Cdk4 Cdk6
ST
Pax4
E
 *
2.0
1.5
1.0
0.5
0
Fo
ld
 in
cr
ea
se
 a
s 
co
m
pa
re
d
to
 S
T 
co
nt
ro
l a
ni
m
al
s
 *
c-myc
C
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
ST Pax4
%
 B
rd
U
 p
os
iti
ve
 c
el
ls
BRDU+/INS+
BRDU+/INS-
*
N.D.
*
n = 3
74.51 78.59
25.49 21.41
0
20
40
60
80
100
120
ST Pax4
%
 Is
le
t c
el
ls
NON INSULIN POSITIVE CELLS
INSULIN POSITIVE CELLS
n = 3
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
ST Pax4
%
 B
rd
U
 p
os
iti
ve
 c
el
ls
BRDU+/Pdx1+
BRDU+/Pdx1-
n = 3
*
0
10
20
30
40
50
60
70
80
 
%
 P
dx
1 
po
si
tiv
e 
ce
lls
n = 3
ST      Pax4
2.5
